Objective To investigate the clinical efficacy of low-molecular-weight heparin (LMWH) combined with ganglioside (GLS) in the treatment of acute progressive cerebral infarction (APCI).Methods Eighty-four patients diagnosed with APCI and treated in our hospital from March 2010 to June 2012 were randomly divided into two groups. In the treatment group, 42 patients were administered LMWH combined with GLS, and in the control group, 42 patients were administered traditional medicines, including breviscapine, aspirin, and Lipitor. The therapeutic effects of drugs were compared between the two groups and evaluated using the neurological functional deficit score (NFDS).Results The NFDS score had no significant difference between groups before treatment and significantly increased in both groups after 2 and 4 weeks of treatment (P<0.05). The increase in NFDS score was more significant in the treatment group than in the control group (P<0.05).Conclusions Application of LMWH combined with GLS has good clinical efficacy in the treatment of APCI. This medication can significantly alleviate the clinical symptoms and reduce the mortality rate of APCI. It is safe, reliable, and effective to significantly improve the quality of life of patients, and thus is worthy of wide clinical application.